Sobi

Sobi has received market approval by the European Comission for Alprolix, a long-duration protein therapy that protects hemophilia B patients from uncontrolled bleeding.  With a focus on rare diseases, Swedish Orphan…

The Hemophilia Aid Program has just touched down the first batch of treatments in its target developing countries, as part of a 10-year commitment from US Biogen (Massachusetts) and Swedish…